Lipocine
LPCN
27 hedge funds and large institutions have $3.17M invested in Lipocine in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 19 closing their positions.
0.47% less ownership
Funds ownership: 1.05% → 0.58% (-0.47%)
20% less call options, than puts
Call options by funds: $39K | Put options by funds: $49K
31% less funds holding
Funds holding: 39 → 27 (-12)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
76% less capital invested
Capital invested by funds: $13M → $3.17M (-$9.85M)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$134K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$105K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
+$98.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77.3K |
| 5 |
Barclays
London,
United Kingdom
|
+$65.5K |
Top Sellers
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
-$2.31M |
| 2 |
VMI
VHCP Management II
New York
|
-$1.33M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.28M |
| 4 |
RA
Royce & Associates
New York
|
-$489K |
| 5 |
Millennium Management
New York
|
-$460K |
LPCN Hedge Fund Activity: Q1 2018 in Review
27 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2018, worth a combined $3.17M — down 76% from $13M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LPCN and 7 opened new positions — a net loss of 12 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $134K. The largest seller was Carlson Capital, exiting entirely with an estimated $2.31M sold.
- 27 institutional investors held Lipocine (LPCN) as of Q1 2018, down from 39 in Q4 2017.
- Funds reported $3.17M of Lipocine stock for Q1 2018, down 76% quarter-over-quarter.
- 7 funds opened new Lipocine positions in Q1 2018 and 19 closed out, a net change of -12 holders.
- The largest Lipocine buyer in Q1 2018 was Renaissance Technologies, an estimated $134K added.
- The largest Lipocine seller in Q1 2018 was Carlson Capital, an estimated $2.31M sold.
Based on aggregated 13F filings for Q1 2018.